

Contents

A. Introduction.	1
B. Androgen Control of the Pilosebaceous Gland.	2
C. Androgen Production in Women.	4
I. Definition	4
II. Androgen Biosynthetic Pathways	5
III. Interconversion of Androgens	5
IV. Plasma Levels and Blood Production Rates of Androgens	5
V. Origin of Circulatory Androgens in Women	8
1. Testosterone	8
2. Androstenedione	8
3. Dehydroisoandrosterone and Dehydroisoandrosterone Sulphate	8
4. Dihydrotestosterone	8
5. Androstane diols	9
VI. Control of Androgen Production in Women.	9
D. Androgen Transport in Blood	11
I. Testosterone-Binding Globulin	11
1. Existence	11
2. Purification of TeBG	11
3. Characterization of TeBG in Serum	11
4. Steroid-Binding Parameters of TeBG	12
II. Other Plasma Proteins Binding Androgens	12
III. Regulation of TeBG Activity	12
IV. Physiological Role of TeBG Binding of Testosterone	13
1. Relationship Between Testosterone Binding and Testosterone Metabolism	13
2. Control of the Oestrogen-Androgen Balance in Women	13
3. Selective Concentration of Active Molecules at the Target Cell Site	13
E. Hepatic Metabolism	15
F. Control of Plasma Level of Testosterone: Metabolic Clearance Rate	16

G. Mechanism of Androgen Action in Human Skin	18
I. Introduction	18
II. 5α -Reduction of Testosterone into Dihydrotestosterone	19
1. In Vivo Studies	19
2. In Vitro Studies	20
a) Biochemical Characterization	20
b) Physiological Variations	20
c) Control of Testosterone 5α -Reductase in Human Skin	20
d) Pathological Models	23
e) Studies with Cultured Skin Fibroblasts	24
III. Dihydrotestosterone Formation from Other Androgen Precursors	26
1. Androstenedione	26
2. Dehydroisoandrosterone	26
IV. Intracellular Metabolism of Dihydrotestosterone	26
1. Physiological Importance of 3α - and 3β -Androstanediols	26
2. Characterization of the 3-Ketoreductases	27
V. Intracellular Retention of Dihydrotestosterone	27
1. Methodological Problems	27
a) Cultured Fibroblasts	28
b) Cell-Free Extracts	28
2. Characterization of the Androgen Receptor	28
a) Physiochemical Properties.	28
b) Heat Lability	29
c) Dissociation Constant	29
d) Specificity	29
3. Physiological Variations.	29
4. Control of Androgen Receptor Concentration	30
5. Pathological Variations	30
VI. Conclusion	30
H. Clinical and Biological Assessment of Hirsutism	31
I. Clinical Assessment	31
II. Hormonal Investigation of Hirsutism	33
1. Urinary 17-Ketosteroids	33
a) Basal Conditions.	33
b) Tests of Ovarian Function	34
c) Tests of Adrenal Function.	34
2. Plasma Androgens	35
a) Assays of Testosterone	35
b) Assays of Androstenedione	37
c) Dynamic Tests for Plasma Testosterone and Androstenedione	37
d) Ovarian and Adrenal Vein Catheterization	38
e) Dihydrotestosterone	39
f) Other Steroids	39

3. Evaluation of Androstane-diols	40
4. Conclusion	41

I. Hirsutism of Adrenal Origin 43

I. Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency 43

1. Introduction	43
2. Frequency	44
3. Pathophysiology	44
a) General Remarks	44
b) Single or Multiple Enzymes	45
4. Androgen Production in 21-Hydroxylase Deficiency	45
5. Clinical and Hormonal Characteristics of Delayed Onset Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency	46
a) Hormonal Data from the Literature	46
b) Personal Data	47
c) Interpretation of Results	50
6. Identification of the Heterozygous State	50
7. Genetic Linkage Between 21-Hydroxylase Deficiency and the HLA Blood Group System	51
8. Treatment	52
a) Corticosteroid Replacement	52
b) Other Treatments	52

II. Congenital Adrenal Hyperplasia Due to 11 β -Hydroxylase Deficiency 53

1. Pathophysiology	53
2. Clinical Features	54
3. Hormonal Characteristics	54
4. Genetic Transmission	54
5. Treatment	54

III. Virilizing Adrenal Tumours 54

1. Pathology	55
a) Macroscopy	55
b) Histology	55
c) Malignant Criteria	55
2. Steroid Production	55
a) Dehydroisoandrosterone	56
b) Other Androgens	56
3. Clinical Aspects of Virilizing Adrenal Tumours	56
a) Adult Females	56
b) Prepubertal Females	57
4. Hormonal Findings	57
a) Urinary Steroids	57
b) Plasma Steroids	57
c) Dynamic Tests	57
5. Physical Methods for Diagnosis of Virilizing Adrenal Tumours	58
6. Treatment	58

a) Surgical	59
b) Chemotherapy	59
c) Benign Tumours	59
J. Hirsutism of Ovarian Origin	60
I. Polycystic Ovarian Syndrome	60
1. Theory of "Hypothalamic Masculinization"	60
2. Two Types of Polycystic Ovaries.	60
3. LH-RH Test in the Polycystic Ovarian Syndrome	61
4. Clomiphene Test	61
5. Oestradiol Test.	63
6. Androgen Overproduction in Polycystic Ovarian Syndrome.	63
7. Pathophysiology of Polycystic Ovarian Syndrome	64
8. Treatment	66
9. Conclusion	66
II. Virilizing Ovarian Tumours	66
1. Pathological Classification.	67
a) Arrhenoblastoma	67
b) Hilus Cell Tumours	67
c) Lipid Cell Tumours	67
d) Granulosa and Theca Cell Tumours	68
e) Gonadoblastomas	68
f) Functional Stroma Tumours.	68
g) Luteoma	68
2. Steroidogenesis.	68
a) Arrhenoblastoma	69
b) Hilus Cell Tumours	69
c) Luteoma	69
3. Clinical Features	69
4. Hormonal Investigations	70
a) Assays in Basal Conditions	70
b) Dynamic Tests.	70
c) Other Methods for Diagnosis	70
5. Differential Diagnosis.	71
6. Prognosis	71
7. Treatment	72
8. Conclusion	72
III. Ovarian Hyperthecosis	72
K. Idiopathic Hirsutism	74
I. Basis of Androgen Hypersensitivity	74
II. Hypersensitivity Versus Androgen Overproduction	75
III. Clinical and Biological Characteristics	76
1. Criteria for Estimation of Androgen Production	76

Contents	XI
2. Criteria for Estimation of Peripheral Androgen Consumption . .	77
3. Personal Data	77
a) In Vivo Studies	77
b) In Vitro Studies	78
c) Interpretation of Results	79
IV. Treatment	81
V. Conclusion.	81
L. Treatment of Hirsutism	83
I. Introduction	83
II. Methods.	83
1. Oestrogens	83
a) Mechanism of Action.	83
b) Clinical Use	83
2. Progesterone.	85
3. Cyproterone Acetate	86
a) Mechanism of Action.	86
b) Personal Results	86
4. Corticosteroids.	91
III. Conclusion.	91
References.	92
Subject Index	109